Navigation Links
Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Date:3/13/2008

aceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertaintie
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 “This kit has ... to screen from 0 to 150 ppb,” said Mark Tess, ... a significant benefit to plant owners and USDA-GIPSA inspection agencies ... other commodities. Testing can take place in a matter of ... can the plant test the feed and grain before accepting ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... , , , , Multiporator , , , , , ... Transfection Protocol , Protocol No. 4308 915.041 11/2000 , , ... , , Cell line , ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), ...
... , , , , , , Multiporator / Electroporator 2510 , , , ... , Transformation Protocol , Protocol No. 4308 915.531 ... , , , , , , ... , Cell type , ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.525 01/2002 , ... , , , , ... , Cell type , Bacteria, gram positive, ...
Cached Biology Technology:T98G 2Saccharomyces cerevisiae 2Nocardia asteroides 2
(Date:8/29/2014)... stretch them, twist them, fold them: modern materials that ... potential, whether as artificial skin or electronic paper. , ... a challenge but a new way of working with ... a game-changer. , Previous success in the field ... use of precious gold and silver nanowires. , ...
(Date:8/28/2014)... Yale University researchers have identified a handful of bacterial ... as Crohn,s disease and ulcerative colitis, using patients, own ... are published Aug. 28 in the journal Cell ... intestinal microbiota, which plays a critical role in the ... only a small number of bacterial species affect a ...
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research Careers) ... American Society of Human Genetics from October 18 ... are meant to promote the entry of students, post ... of the basic science community and to encourage the ... Human Genetics. This year MARC conferred 16 awards ...
Breaking Biology News(10 mins):Copper shines as flexible conductor 2Yale study identifies possible bacterial drivers of IBD 2
... Valley, NY. (Feb. 13, 2013) Researchers at the ... Medical Research Centre in Warsaw, Poland, have found that ... of immunocompetent research mice when the grafts are injected ... injected into the forceps minor (FM) region. In ...
... plants, far from being passive wallflowers, are "secret gardeners" that ... survival, says a team of scientists from Duke University and ... have long believed that the distribution of plants within a ... different elevations because that,s where conditions like soil aeration and ...
... tissues, diseased organs and tumors inside the body without x-rays ... to the level of atoms? Doctors could make visual diagnoses ... of DNA, watching molecules misfold, or identifying a cancer cell ... associate professor of physics at The City College of New ...
Cached Biology News:Impact of stem cell transplantation location in brain a crucial factor for cell survival 2Marsh plants actively engineer their landscape 2Team creates MRI for the nanoscale 2
pH-insensitive fluorescence (pH 2-12)...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
KRIT1 Immunogen: KRIT1 (NP_004903, 637 a.a. ~ 737 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Biology Products: